ErbB signalling pathway is frequently found overly active in malignancies of epithelial origin, accounting for 80–90% of all cancer cases, mainly due to gene amplification, point and deletion mutations, or gene fusion, suggesting this pathway as a very attractive target in the oncology field [42,43,44,45,46,47,48,49]. This evidence concerns the gene EGFR and cancer.